# Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

> **NCT04697953** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Age-related Macular Degeneration (AMD)

## Interventions

- **DRUG:** brolucizumab

## Key facts

- **NCT ID:** NCT04697953
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05-31
- **Primary completion:** 2021-06-21
- **Final completion:** 2025-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study terminated - no participants were enrolled.
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04697953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04697953, "Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04697953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*